METHODS OF USE RELATED TO XEROSTOMIA
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and neck cancer.
-
Citations
40 Claims
-
1-21. -21. (canceled)
- 22. A method for treating xerostomia associated with radiation therapy for head and neck cancer in a human, which comprises administering to said human a therapeutically effective amount of a lyophilized dosage form comprising a thermally stable, sterile, crystalline amifostine trihydrate, wherein the dosage of the crystalline amifostine trihydrate is about 200 mg/m2.
-
23-24. -24. (canceled)
-
30. (canceled)
-
33-36. -36. (canceled)
-
40. A method for treating xerostomia associated with radiation therapy for head and neck cancer in a human, which comprises administering to said human a therapeutically effective amount of a dosage form comprising a thermally stable, sterile, crystalline amifostine trihydrate, wherein the dosage of the crystalline amifostine trihydrate is about 200 mg/m2 administered by intravenous infusion for 3 minutes.
Specification